drugset
drugset / Trial / NCT07249905

Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma

NCT07249905 ↗

Phase 1/2 Recruiting 180 enrolled ModeX Therapeutics, An OPKO Health Company
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2003 in patients with different types of lymphoma

Timeline

Start
2026-04-13
Primary completion
2028-01
Completion
2030-04

Drugs

EvaluationDrugModalityDoseRoute
Subject MDX2003 Unknown — Intravenous

Indications

Waldenstrom macroglobulinemia follicular lymphoma high grade B-cell lymphoma primary mediastinal large B-cell lymphoma